Autism Spectrum Disorder (ASD) is a group of a broad range of conditions in which the impact is directly on the brain of a human body. It is a complex neurodevelopmental condition. Autism Spectrum Disorder is a developmental disability that results in the impairment in mostly three areas: social interaction, communication or use of verbal and non-verbal language. The exact cause of Autism spectrum disorder is still unknown. However, the probability of genetic predisposition, some environmental factors or a combination of both has not been ruled out. Autism is not one type of problem but every person suffering from Autism spectrum disorder experiences and behaves differently. People with autism might be able to solve hard, complex puzzles in a jiffy but when it comes to regular day-to-day talking or interacting with anyone, they show the state of regression. They learn, think, feel, behave and act in a different manner not same as everyone else.
Autism Spectrum Disorder Epidemiology
Autism Spectrum Disorder occurs in all the racial, ethnic, and socioeconomic groups, but is about 4 times more common among boys than in girls. As per DelveInsight’s estimates, the Autism Spectrum Disorder’s Incident population in 7 major markets (MM) was found to be 6,545,050 in 2016. Among all the countries, the Autism Spectrum Disorder’s prevalent cases in the United States accounts for the highest number of around 3,734,939 cases in 2016. ASD’s Incident population in the UK was the highest with 655,612 cases. The Autism Spectrum Disorder prevalence in Italy followed, where it was 357,235 in 2016
Autism Spectrum Disorder Market
As per DelveInsight’s assessment, Autism Spectrum Disorder’s market size in 7MM was found to be USD 2510.2 million in 2016 for the study period (2016-2027). Among EU5 countries, the United Kingdom had the highest ASD’s market share with USD 255.21 million, while the Autism Spectrum Disorder Market in Germany was the lowest of around USD 35.16 million in 2016.
A key factor driving the growth of the Autism Spectrum Disorder Market can be the funding from the various government organizations. The US NIH in 2017 awarded USD 100 million for the development of interventions for Autism Spectrum Disorder. Medicare in Australia too announced new offers to diagnose Autism and promote early interventions. However, the diagnosis and management of ASD is a bit of a challenge. No pharmacological treatment currently exists to help improve the problems that individuals may experience with social skills, repetitive behaviors, restrictive interests, and communication.
Autism Spectrum Disorder Therapies
Most medicines prescribed to ease the disabling symptoms of Autism Spectrum Disorder are used “off label”. These off-label medicines can only help to relieve signs and symptoms associated with ASD but not cure the disorder fully. The drugs commonly prescribed to Autism Spectrum Disorder patients include antipsychotics antidepressants, selective serotonin reuptake inhibitors, stimulants, anticonvulsants, anti-hypertensives, CNS depressants, and many others. Risperidone (Johnson and Johnson) and Aripiprazole (Otsuka Pharmaceuticals) are the only two antipsychotics that so far have been approved by the FDA but even they have got their share of side effects and limitations.
Many alternative and complementary therapies such as behavior and communication therapies, education therapies, family therapies, creative therapies (art therapy or music therapy), sensory-based therapies, special diets, chelation therapy,
Autism Spectrum Disorder Pipeline Products
Many players such as Roche, Neurochlore/Servier, Nobelpharma, Johnson and Johnson, Yamo Pharmaceuticals, Curemark etc. are involved in improving the Autism Spectrum Disorder Therapies. Balovaptan, developed by Roche, is a vasopressin receptor antagonist (VRA), is under Phase III trial, a candidate to treat both children and adults with Autism Spectrum Disorder, was granted Breakthrough Therapy Designation by US FDA. Expected to launch by 2021, DelveInsight Autism Spectrum Disorder Forecast says that it holds the highest share in Autism Spectrum Disorder Market during the forecast period of 2017-27. Curemark’s drug CM-AT, under Phase III trial, received the Fast Track Designation for Autism Spectrum Disorder and the company has also begun rolling NDA submission of CM-AT for its treatment. Another Fast Track Designated drug by FDA, L1-79 developed by Yamo Pharmaceuticals, has been proved to be a well-tolerated therapy. Bumetanide- one of the most looked upon drug candidate for Autism Spectrum Disorder, being developed by Neurochlore/ Servier, promises to show a success rate in treating ASD in children. It might out throw the two FDA-approved drugs namely Risperdal and Apiriprazole and can be a winning member in Autism Spectrum Disorder Competitive landscape.
To fulfill the present unmet needs of the ASD market and to provide better options for ASD treatment, various research studies are ongoing to develop a novel therapy for Autism Spectrum Disorder. Overall, an increase in the awareness of the condition, paradigm shifts in the diagnostic approach and the launch of future treatments will significantly shift the Autism Spectrum Disorder’s market during the forecast period (2018-2027).